Grant: Idea to Innovation
McMaster University
$122,500.00
A High Throughput Platform for Multiplexed Screening of Drugs of Abuse by Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
FY 2016-17
Summary
New technologies are urgently required for more accurate yet reliable screening of drugs of abuse (DoA) given the worldwide epidemic of addiction to pain relief opioids and other classes of prescription medications. The socioeconomic impacts to the prescription drug abuse problem in Canada has been devastating to public health care and the criminal justice system, including mental illness and substance abuse, lost productivity, and an alarming increase in deaths due to drug overdose, such as the highly potent synthetic opioid, fentanyl. This project will introduce a high throughput platform for multiplexed screening of DoA in urine samples using multisegment injection-capillary electrophoresis-mass spectrometry (MSI-CE-MS) that is suitable for implementation within an accredited clinical or forensic toxicology laboratory. Current approaches for primary screening of DoA rely on immunoassays that are prone to false positives and false negatives due to poor selectivity, which are not applicable to emerging classes of drugs due to the unavailability or long delays to access of viable antibody reagents that target only a single drug. Although liquid chromatography-tandem mass spectrometry (LC-MS/MS) is used for confirmatory testing of screen-positive urine samples, it is not suitable for primary screening due its lower sample throughput and targeted nature of chemical analysis. We will overcome these limitations by optimizing and rigorously validating a patented screening technology based on MSI-CE-MS that relies on serial injections of up to ten urine samples within a single run (< 3 min/sample), where multiplexed electrophoretic separations are coupled to high resolution, accurate MS with full-scan data acquisition using a time-of-flight mass analyzer. This approach will offer a more selective, precise and less costly format for primary screening with high data fidelity, which will also enable unambiguous identification and detection of virtually an unlimited panel of DoA above accepted cut-off limits. Non-targeted drug screening based on MSI-CE-MS will also enable the discovery of new classes of lethal opioid analogs in adulterated or laced street drugs consumed at great risk by end-users. This innovative technology will introduce a superior screening platform to conventional immunoassays as required for more effective therapeutic drug monitoring programs and improved patient care while preventing drug diversion and tragic cases of accidental drug overdose.
Program
Idea to Innovation
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
501959-2016
Name nom
BritzMcKibbin, Philip
Department département
Chemistry & Chemical Biology
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
122500
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
3504
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Bioanalytical chemistry
Research subject fr
Chimie bioanalytique
Partie
1
Nb partie
1
Application title
A High Throughput Platform for Multiplexed Screening of Drugs of Abuse by Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Keyword
NSERC
Application summary
New technologies are urgently required for more accurate yet reliable screening of drugs of abuse (DoA) given the worldwide epidemic of addiction to pain relief opioids and other classes of prescription medications. The socioeconomic impacts to the prescription drug abuse problem in Canada has been devastating to public health care and the criminal justice system, including mental illness and substance abuse, lost productivity, and an alarming increase in deaths due to drug overdose, such as the highly potent synthetic opioid, fentanyl. This project will introduce a high throughput platform for multiplexed screening of DoA in urine samples using multisegment injection-capillary electrophoresis-mass spectrometry (MSI-CE-MS) that is suitable for implementation within an accredited clinical or forensic toxicology laboratory. Current approaches for primary screening of DoA rely on immunoassays that are prone to false positives and false negatives due to poor selectivity, which are not applicable to emerging classes of drugs due to the unavailability or long delays to access of viable antibody reagents that target only a single drug. Although liquid chromatography-tandem mass spectrometry (LC-MS/MS) is used for confirmatory testing of screen-positive urine samples, it is not suitable for primary screening due its lower sample throughput and targeted nature of chemical analysis. We will overcome these limitations by optimizing and rigorously validating a patented screening technology based on MSI-CE-MS that relies on serial injections of up to ten urine samples within a single run (< 3 min/sample), where multiplexed electrophoretic separations are coupled to high resolution, accurate MS with full-scan data acquisition using a time-of-flight mass analyzer. This approach will offer a more selective, precise and less costly format for primary screening with high data fidelity, which will also enable unambiguous identification and detection of virtually an unlimited panel of DoA above accepted cut-off limits. Non-targeted drug screening based on MSI-CE-MS will also enable the discovery of new classes of lethal opioid analogs in adulterated or laced street drugs consumed at great risk by end-users. This innovative technology will introduce a superior screening platform to conventional immunoassays as required for more effective therapeutic drug monitoring programs and improved patient care while preventing drug diversion and tragic cases of accidental drug overdose.